← Back to Search

Apoptosis Inducer

BAY2666605 for Melanoma

Phase 1
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 28 + 14 days
Awards & highlights

Study Summary

This trial is being done to learn more about a new substance called BAY2666605 that may help treat advanced cancer by triggering cell death.

Eligible Conditions
  • Metastatic Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 28 + 14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 + 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AUC(0-24) of BAY2666605
AUC(0-24)md of BAY2666605
Cmax,md of BAY2666605
+4 more
Secondary outcome measures
DCR
DOR
ORR
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dose expansion of BAY2666605Experimental Treatment1 Intervention
Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.
Group II: Dose escalation of BAY2666605Experimental Treatment1 Intervention
Approximately 7 or 8 dose levels are planned.

Find a Location

Who is running the clinical trial?

BayerLead Sponsor
2,230 Previous Clinical Trials
25,325,632 Total Patients Enrolled
13 Trials studying Melanoma
779 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper limit of participants allowed in this experiment?

"Indeed, clinicaltrials.gov displays that this research is still recruiting participants. This experiment was first published on April 15th 2021 and was recently amended on November 14th 2022; 89 individuals need to be recruited from 5 different medical centres."

Answered by AI

What objectives has this trial been designed to achieve?

"As stated by the trial's sponsor, Bayer Pharmaceuticals, the primary objective over a 6 month window will be to measure DLTs (dose-limiting toxicities) at each dose level in the dose escalation period. Additionally, secondary outcomes such as DOR (duration of response), DCR (disease control rate), and ORR (objective response rate) will also be examined."

Answered by AI

How many institutions are overseeing this clinical research?

"Participants can enroll in this trial via five clinical sites, including South Texas Accelerated Research Therapeutics, LLC (San Antonio), Yale University School of Medicine (New Haven), and Sarah Cannon Development Innovations (Nashville). Additionally, there are two other locations."

Answered by AI

Does this research endeavor currently have open slots for participants?

"Affirmative. Clinicaltrials.gov data indicates that, as of November 14th 2022, this medical trial is actively searching for participants; it was originally posted in April 15th 2021. 89 patients need to be recruited from 5 separate sites."

Answered by AI

Has BAY2666605 been approved by the US Food and Drug Administration?

"Considering the limited safety and efficacy data, BAY2666605 earned a score of 1 on our team's scale from 1 to 3."

Answered by AI
~1 spots leftby Mar 2025